Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 12/14 09:23:55 am
78.49 EUR   -0.14%
10/31SANOFI : Shares Jump After Healthy 3Q -- Update
DJ
10/31Vaccines and Genzyme help Sanofi keep promise of return to growth
RE
10/26SANOFI SA : quaterly earnings release
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : plans 670 job cuts in France by end 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/05/2018 | 06:09pm CET
The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris

PARIS (Reuters) - French drugmaker Sanofi told unions on Wednesday it was planning to cut 670 jobs in France, a union representative told Reuters.

The plan, which is to be set on a voluntary basis, would affect human resources, IT, and finances among others, Thierry Bodin, with the CGT union said. In addition, 80 IT jobs are to be outsourced, he said.

"This is a terrible loss of expertise. It will have consequences in terms of efficiency," Bodin said.

Sanofi had said in September it would continue to implement cost savings after having reached a 1.5 billion euros (1.34 billion pounds) cost reduction target a year ahead of expectations.

"We are blindsided as Sanofi makes significant amounts of profits. And at a time of strong social tensions in France, the government is looking the other way," Bodin said in reference to the so-called "yellow vest" protests which led to the worst riots seen in central Paris in five decades last Saturday.

A Sanofi spokesman confirmed the company's intention to shed 670 jobs out of a 25,000 workforce in France and said the plan was to be completed by the end of 2020.

At the same time, Sanofi will invest 700 million euros in France to upgrade its production sites, notably in the areas of vaccines manufacturing and other biologic medicines.

(Reporting by Matthias Blamont; Editing by Leigh Thomas and Mathieu Rosemain)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
12/11SANOFI : DOH says Dengvaxia ban likely to stay
AQ
12/11FDA biosimilars policies will bring interchangeable insulin to market
AQ
12/11MyoKardia Sees Topline Results from Phase 1b Study of MYK-491
DJ
12/11BIOCENTURY - MANAGEMENT TRACKS : Grail, EUSA
AQ
12/11SANOFI : 'Truth isn't truth' tops list of notable quotes in 2018
AQ
12/10SANOFI : Boehringer Ingelheim plans to cut about 300 jobs in France
RE
12/07EXCLUSIVE - ACTIVIST INVESTOR ELLIOT : sources
RE
12/07EXCLUSIVE : Activist investor Elliott has stake in Germany's Bayer - sources
RE
12/06Euro Health Stocks No Longer Insulated From Global Selloff -- Market Talk
DJ
12/06SANOFI : Sema4, Mount Sinai collaborate on largest Asthma study of its kind
AQ
More news
Financials (€)
Sales 2018 35 000 M
EBIT 2018 8 388 M
Net income 2018 5 006 M
Debt 2018 17 026 M
Yield 2018 3,92%
P/E ratio 2018 18,90
P/E ratio 2019 17,74
EV / Sales 2018 3,30x
EV / Sales 2019 3,18x
Capitalization 98 424 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 82,3 €
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI9.39%111 713
JOHNSON & JOHNSON5.81%394 519
PFIZER23.05%256 128
NOVARTIS6.84%226 072
ROCHE HOLDING LTD.3.96%222 010
MERCK AND COMPANY40.41%202 855